celecoxib oral / Generic mfg. - LARVOL DELTA

Innovation Versus Consolidation: Critical Reflections on Suzetrigine and the Tramadol-Celecoxib Co-Crystal. (PubMed, J Pain Palliat Care Pharmacother) - No abstract available

Journal

Celecoxib in oncology: targeting the COX-2/PGE2 axis to reprogram the tumor immune microenvironment and enhance multimodal therapy. (PubMed, Front Pharmacol) - "Despite the breakthrough of celecoxib in the field of oncology treatment, large-scale trials are warranted to validate its long-term safety and biomarker-driven accuracy. This work underscores the potential of celecoxib as a cornerstone in multimodal cancer therapy and provides a roadmap for its integration into personalized treatment paradigms."

IO biomarker • Journal • Review • Oncology

Interdisciplinary pharmaceutical care model engaging patient participation alleviate the anticholinergic burden in community-dwelling older adults: subgroup analysis of a randomized controlled trial. (PubMed, Ther Adv Drug Saf) - "Famotidine, tramadol, alprazolam, and celecoxib were the most commonly prescribed and discontinued S-type AC drugs. This community-based interdisciplinary pharmaceutical care model, which included patient participation, was effective in reducing the burden of S-type AC drugs among older adults in rural communities."

Journal • Alzheimer's Disease • Cognitive Disorders • Xerostomia

Real-world experience of low-dose nivolumab combined with metronomic chemotherapy in rural northeast India (ESMO Asia 2025) - "Low-dose nivolumab combined with triple metronomic chemotherapy with Erlotinib, Methotrexate and Celecoxib, demonstrated a favorable safety profile, with predominantly grade 1–2 adverse events; only 7% experienced grade 3 or higher toxicities, leading to dose modifications in 11% of cases. Low-dose nivolumab combined with metronomic chemotherapy is a feasible, well-tolerated, and effective option for advanced cancers in rural Northeast India, addressing critical barriers of cost and access. Given that prior studies show only about 3% of Indian patients eligible for immunotherapy can afford standard doses, this low-dose approach offers a practical strategy to expand immunotherapy availability in resource-limited settings."

Clinical • Real-world • Real-world evidence • Gastric Cancer • Gastrointestinal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Efficacy & safety of taxane-platinum doublet chemotherapy with triple oral metronomic chemotherapy & low dose nivolumab as neoadjuvant therapy in locally advanced head and neck squamous cell carcinoma (ESMO Asia 2025) - "While the standard neoadjuvant TPF regimen (taxane, platinum, 5-fluorouracil) improves survival, it's use is limited by toxicity & resource constraints. A regimen with Taxane & Platinum—TP with triple oral metronomic chemotherapy (OMCT: methotrexate, erlotinib, celecoxib)—has shown favorable responses with lower toxicity. We assessed the efficacy and safety of adding low dose Nivolumab to TP-OMCT. This single-centre observational study- (Jan 2024–May 2025) -enrolled LA- HNSCC patients treated with neoadjuvant weekly paclitaxel (80mg/m2),carboplatin (AUC-2), triple-OMCT, and low-dose nivolumab (20, /40, or /80 mg)... Our chemo-immunotherapy regimen appears well-tolerated and highly effective. Compared to published literature, the pCR and survival outcomes were encouraging, warranting longer follow-up and validation in prospective studies."

Clinical • Metastases • Head and Neck Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck

Adebrelimab combined with Celecoxib and chemotherapy as first-line treatment for PD-L1-positive and HER2-negative locally advanced gastric/gastroesophageal junction adenocarcinoma: A single-arm, exploratory clinical trial (ESMO Asia 2025) - P4 | "Eligible patients will receive a combination of adebrelimab, celecoxib, and either XELOX or SOX, administered once every 21-day cycle, and continued until disease progression, unacceptable toxicity, withdrawal of informed consent, or investigator-determined study termination. The secondary endpoints include disease control rate, duration of response, progression-free survival, overall survival, and safety. Exploratory endpoints included the correlation between COX-2 expression and treatment efficacy and prognosis, as well as the association of cytokines IL-6, IL-8, and IL-10 with efficacy and prognosis."

Clinical • IO biomarker • Metastases • Esophageal Cancer • Gastric Adenocarcinoma • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CXCL8 • HER-2 • IL10 • IL6 • PTGS2

A phase 2 trial of TAS-102 with or without celecoxib in ctDNA-defined minimal residual disease (MRD) in colorectal cancer after completion of adjuvant chemotherapy. (ASCO-GI 2026) - P2 | "Funded by Taiho Oncology, Inc Clinical Trial Registration Number: NCT05343013 The full, final text of this abstract will be available on Jan 05 at 05:00 PM EST."

Circulating tumor DNA • Clinical • Minimal residual disease • P2 data • Residual disease • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Elucidating the Mechanisms of Chrysanthemum Action on Atopic Dermatitis via Network Pharmacology and Machine Learning. (PubMed, Int J Mol Sci) - "To experimentally validate these findings, HaCaT keratinocytes were co-stimulated with TNF-α and IFN-γ to establish an in vitro inflammatory model, and co-treatment with three major flavonoids from Chrysanthemum-Acacetin, Diosmetin, and Chryseriol-significantly suppressed cytokine-induced COX-2 overexpression and reduced NF-κB p65 phosphorylation, confirming their inhibitory effects on NF-κB activation. These results were consistent with molecular docking and dynamics simulations, which demonstrated that these flavonoids, along with celecoxib, could stably bind to COX-2, thereby enhancing system stability and reducing residue fluctuations at the binding interface, revealing the molecular basis by which Chrysanthemum alleviates AD and supporting its modernization and therapeutic potential."

Journal • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • IFNG • MMP9 • PACERR • PTGS2 • TNFA

Etoricoxib-Induced Fixed Erythema. (PubMed, J Clin Med) - "Patch testing was negative, while oral challenge confirmed etoricoxib-induced FDE; celecoxib was subsequently evaluated as a potential safe alternative. This case underscores the importance of an integrated diagnostic approach-including careful history, clinical examination, and confirmatory testing-to accurately diagnose delayed cutaneous drug reactions and to identify safe therapeutic options for patients."

Journal • Cardiovascular • Dermatology • Endocrine Disorders • Hypertension • Immunology • Pruritus • Renal Calculi • CD8

Current state of machine learning implementation in pharmaceutical process modeling for oral solid dosage forms. (PubMed, Int J Pharm) - "While ML demonstrates promise in enabling requirements of advanced manufacturing, challenges remain in data availability, model interpretability, extrapolation, uncertainty quantification, and integration with existing manufacturing workflows. Future directions include integrating ML with digital twins, addressing model scalability to work across different scales, and incorporating uncertainty quantification to increase reliability and decision-making in dynamic variable process environments."

Journal • Review

Gentisic acid ameliorates lumbar disc herniation by regulating M1/M2 Polarization via the MAPK14/S100A9/Rac1/2 pathway. (PubMed, Cell Biol Toxicol) - "In vivo experiments demonstrate that Gentisic acid ameliorates disc injury, improves neurological function, and alleviates pain in a rat LDH model, with efficacy comparable to celecoxib. These results suggest that Gentisic acid could alleviate LDH symptoms by modulating macrophage polarization and autophagy through the MAPK14/S100A9/Rac1/2 axis, offering a promising therapeutic strategy for LDH."

Journal • Musculoskeletal Diseases • Pain • MAPK14 • S100A9

Randomized open-label non-inferiority trial of paracetamol or celecoxib for patients with chronic low back pain. (PubMed, Sci Rep) - "Paracetamol had a superior effect on pain-related psychological variables and quality of life compared to celecoxib. These results suggest that paracetamol provides analgesic effects comparable to celecoxib for CLBP, meeting the criteria for non-inferiority."

Head-to-Head • Journal • Back Pain • Lumbar Back Pain • Musculoskeletal Pain • Pain

Henoch-Schönlein purpura induced by sitagliptin: A case report. (PubMed, SAGE Open Med Case Rep) - "Sitagliptin was discontinued, and the patient was treated with celecoxib, colchicine, and cefadroxil for wound infection. However, urinalysis revealed new 0.3 g/L protein. Overall, this case highlights a new potential association of dipeptidyl peptidase-4 inhibitors with Henoch-Schönlein purpura, which may have systemic consequences."

Journal • Diabetes • Infectious Disease • Metabolic Disorders • Type 2 Diabetes Mellitus • Vasculitis

Opportunities and challenges for the implementation of pharmacogenomics in supportive care for gastrointestinal cancer patients in Zimbabwe. (PubMed, Pharmacogenomics) - "PGX guidelines were fully implemented for tramadol, codeine, omeprazole, and ondansetron; partially for ibuprofen and celecoxib; and unimplementable for amitriptyline. There is an opportunity to improve supportive care in gastrointestinal cancer patients through pharmacogenomics though some specific medicines challenges to full implementations are due to limited registered medicines."

Biomarker • Journal • Gastrointestinal Cancer • Oncology • Solid Tumor

Predictive Role of Circulating Tumor DNA in Stage III Colon Cancer Treated With Celecoxib: A Post Hoc Analysis of the CALGB (Alliance)/SWOG 80702 Phase 3 Randomized Clinical Trial. (PubMed, JAMA Oncol) - P3 | "Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer...This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer...The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. ClinicalTrials.gov Identifier: NCT01150045."

Circulating tumor DNA • Clinical • Journal • P3 data • Retrospective data • Colon Cancer • Colorectal Cancer • Hematological Malignancies • Leukemia • Microsatellite Instability • Oncology • Solid Tumor • MSI • PIK3CA

Oncolytic Reovirus-Induced Prostaglandin E2 Production in Human Tumor Cells. (PubMed, Biol Pharm Bull) - "A nuclear factor-kappa B (NF-κB) inhibitor, BAY11-7082, and a cyclooxygenase 2 (COX2) inhibitor, celecoxib, significantly inhibited PGE2 secretion, indicating that NF-κB and COX2 played a crucial role in reovirus-induced PGE2 production. These results indicate that reovirus replication in tumor cells is important for reovirus-induced PGE2 production. Attention should be paid to possible PGE2 production in tumors following reovirus treatment."

Journal • Oncology • CTSS

Celecoxib in Parkinson Disease as Adjuvant Therapy (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: Tanta University | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Movement Disorders • Parkinson's Disease

Multicenter randomized controlled trial of Yiqi Huoxue formula() for the treatment of ruptured lumbar disc herniation (PubMed, Zhongguo Gu Shang) - "After treatment with Yiqi Huoxue formula, patients with ruptured LDH show significant improvement in clinical symptoms and a marked reduction in the volume of herniated discs. During the follow-up period, no obvious adverse drug reactions are observed in patients, and no recurrence of symptoms is found at the last follow-up, indicating that the formula has safe and reliable efficacy."

Clinical • Journal • Musculoskeletal Diseases • Orthopedics

Flow cytometric identification of dynamic immune cell populations in a rat model of post-traumatic elbow contracture. (PubMed, Connect Tissue Res) - "Another injured group was treated with celecoxib to determine if changes due to anti-inflammatory treatment could be detected...Comparisons between flow cytometry and previously published mechanics and histology revealed additional insights about temporal patterns in cell-, tissue-, and joint-level changes. Future work will investigate whether changes in immune cells attenuate PTJC symptoms."

Journal • Preclinical • CD8 • PTPRC

Electrochemical 2-Deoxyglycosylation of N-Containing Molecules with β-Stereoselectivity. (PubMed, Org Lett) - "Notably, this strategy is successfully applied to the N-glycosylation of nonsteroidal anti-inflammatory drug celecoxib. Collectively, this protocol provides a greener and more practical strategy for N-glycosylation, enabling the efficient modification of nitrogen-containing drug molecules."

Journal

PICC: Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer (clinicaltrials.gov) - P2 | N=270 | Recruiting | Sponsor: Sun Yat-sen University | N=150 ➔ 270

dMMR • Enrollment change • Mismatch repair • MSI-H • Colon Adenocarcinoma • Colon Cancer • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI

Development of explainable machine learning models to predict side effects in patients with rheumatoid arthritis taking methotrexate treatment: a nationwide multicentre cohort study. (PubMed, BMJ Open) - "Interpretable ML models using real-world clinical data can accurately predict SE in patients with RA taking MTX. These models may facilitate early identification of high-risk individuals and inform personalised treatment strategies. Integration into clinical decision support systems could improve MTX safety monitoring. Further prospective validation in external cohorts is warranted."

Adverse events • Journal • Observational data • Retrospective data • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Exploring early add-on celecoxib treatment in OCD: Results from a preliminary randomized, double-blind, placebo-controlled trial. (PubMed, J Psychopharmacol) - "Celecoxib holds promise as a potentially safe early add-on treatment in OCD for rapid improvement in psychopathology, with further research warranted in this area."

Clinical • Journal • Inflammation • Mood Disorders • Obsessive-Compulsive Disorder • Psychiatry • BDNF • IL6

A Comparative Assessment of the Efficacy and Toxicity Profiles of Dual and Triple Oral Metronomic Chemotherapy in Advanced Head and Neck Cancers in a Tertiary Care Center. (PubMed, Cureus) - "Background The standard of care for unresectable or metastatic advanced head and neck squamous cell carcinoma (HNCSCC) is either immunotherapy, cetuximab-based monotherapy, or combination therapy...The patients received methotrexate 40 mg/m² PO weekly, celecoxib 200 mg twice daily, with or without erlotinib 150 mg daily...Palliative radiotherapy quadrupled the PFS and nearly doubled the OS in HNCSCC, even in patients with prior exposure to radiotherapy. These findings suggest a potential benefit in utilizing triple therapy in combination with palliative radiotherapy for specific subgroups of patients with HNCSCC, warranting further prospective clinical trials to validate these results."

Journal • Head and Neck Cancer • Mucositis • Oncology • Oral Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Stomatitis

Epidemiology and Risk Factors for Arthrofibrosis Following Total Knee Arthroplasty: Towards Effective Prevention. (PubMed, J Knee Surg) - "Prevention strategies focus on patient education, rehabilitation, and pharmacological interventions, with emerging evidence supporting the use of celecoxib, dexamethasone, COX-2 inhibitors, and losartan in reducing the risk of arthrofibrosis. Despite progress, gaps remain, particularly regarding standardized definitions and high-quality randomized controlled trials to assess the optimal treatment methods."

Journal • Orthopedics • Pain